Skip to main content

Table 1 Baseline demographics and patient characteristics

From: Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

Characteristic Total (N = 18)
Sex, n (%)
 Male 12 (66.7)
 Female 6 (33.3)
Age (mean), years 49.1
 Median (range) 49.5 (23–65)
ECOG performance status, n (%)
 0 8 (44.4)
 1 10 (55.6)
TNM stage, n (%)
 IIIA 1 (6)
 IV 17 (94)
Previous regimens of systemic therapies
 Median (range) 3.5 (1–9)
Tumor type, n (%)
 NSCLC 5 (27.8)
 Colorectal cancer 7 (38.9)
 Ovarian cancer 1 (5.6)
 Gastric cancer 1 (5.6)
 Thyroid cancer 1 (5.6)  
 DLBCL 1 (5.6)  
 Fibrosarcoma 1 (5.6)  
 Renal cancer 1 (5.6)  
  1. ECOG Eastern Cooperative Oncology Group, NSCLC non-small-cell lung cancer, DLBCL diffuse large B cell lymphoma